Host Directed Therapeutics for treatment for viral disease – Open Topic
Closed Solicitation Posted
- Solicitation number
- CBD244-P001
- Agency
-
Joint PEO Chemical and Biological Defense
Acquisition Support Center, Department of Defense
- Responses due
- Set-aside
- Total Small Business
Opportunity facts
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- More information
Notice details come from DoD SBIR/STTR (DSIP). Updated .
About this opportunity
The Department of the Army Acquisition Support Center's Joint PEO Chemical and Biological Defense seeks Phase I SBIR proposals under open topic CBD244-P001 for broadly active host-directed therapeutics to treat viral disease, with proposals due September 24, 2024, a deadline that has passed. The set-aside is Total Small Business.
The topic seeks therapeutics, alone or in combination, for treatment or prophylactic medical countermeasures against viral infections including Filoviruses, Alphaviruses, Arenaviruses, Paramyxoviruses, Orthopoxviruses, and Hantaviruses. Phase I requires developing viral strains or surrogate screening assays, identifying inhibitors of viral replication, and assessing in vitro antiviral activity, host response parameters, and cytotoxicity. Human subjects, biospecimens, and animal research are prohibited in Phase I and permissible in Phase II, subject to separate DoD-level approval from U.S. Army Medical Research and Development Command and the Defense Threat Reduction Agency Research Oversight Board. Per the submission instructions attachment, Phase I awards carry a maximum of $204,582.00 for up to six months of performance, with a 20-page technical volume limit. Phase II proposals require a prior Phase I award and may be submitted no sooner than five months after that award; budgets cover 24 months, typically on a cost-plus fixed fee basis. The program does not accept Direct to Phase II or Technical and Business Assistance proposals.
Proposals are submitted through the Defense SBIR/STTR Innovation Portal and must include a coversheet, technical volume, cost volume, Company Commercialization Report, supporting documents, Fraud Waste and Abuse training certification, and Foreign Affiliations Disclosure webform. Offerors must disclose foreign nationals, green card holders, and dual citizens involved in the project, regardless of export control applicability. Small business concerns may submit one proposal per open topic; multiple submissions render all prior proposals nonresponsive. The topic is not ITAR-controlled. The topic Q&A closed September 10, 2024 at 12:00 p.m. ET. The NAICS code is 541715 and the PSC is AC12.
Notice text
DoD SBIR topic CBD244-P001
Component: CBD
Command: CBD
Phase: SBIR Program Phase I Action
Technology Areas: Chem Bio Defense
Focus Areas: Biotechnology
Keywords: host-directed; antiviral; small molecule; biopharmaceutical; Bunyavirus; Arenavirus; Viral Hemorrhagic Fever; Alphavirus; Ebolavirus; Filovirus; Paramyxovirus
ITAR: No
Objective:
The goal of this SBIR is to develop and demonstrate efficacy of broadly active host directed therapeutics to be used as treatment, either as sole agents or as combination agents, in the event of disease or as prophylactic medical countermeasures (MCM) following human exposure or threat of exposure to viral infections of interest.
Description:
Host-directed Therapeutics (HDTs) are therapies that target either human host factors or pathways that are necessary for a virus to replicate/propagate, or the host responses to infection that lead to disease symptoms. HDTs increase or decrease the production of host factors that affect viral replication and propagation, and other target host antiviral responses. In contrast, direct-acting antiviral (DAAs) therapeutics directly target the function of viral proteins. Unlike DAAs, HDTs are generally expected to be effective against drug resistant mutants and some HDTs would provide a higher barrier to resistance. HDTs are expected to be effective against multiple serotypes (e.g., Dengue), clades (HIV) or genotypes (HCV). HDTs can potentially be broad acting (activity against several families) counter measures that can be used either as a PEP or treatment in conjunction of DAAs. Disease signs (measurable medical responses to infection) and symptoms (infection responses felt by the patient such as headache) including hemorrhagic fevers, encephalitis, musculoskeletal disease, acute respiratory distress syndrome, and paralysis are largely dependent upon the viral pathogen’s mechanism of pathogenesis, including cell tropism, pathogen mechanism of immune evasion, and specific-host pathogen interactions (intra- and extracellular).
Viral biothreat families of interest to the DOD include: Filoviruses, Togaviruses (Alphaviruses), Arenaviruses, Paramyxoviruses, Poxviruses (Orthopoxviruses), and Hantaviruses. Currently, there are some approved directly acting antivirals for some of these pathogens (ex. TPOXXTM for smallpox treatment, InmazebTM and EbangaTM for Ebola Zaire treatment), however, there are gaps in treatment options for these serious viral infections. This topic solicitation focuses on funding innovative host-directed therapeutic solutions for treatment of infections caused by one or more of these viral families.
Phase I:
The objective of this Phase is to identify broadly-acting host-directed therapeutics against infection by viruses of interest. This Phase will be accomplished by: A) Identification and development of working stocks of appropriate strains of virus(es) for testing. Alternatively, surrogate assays (e.g. pseudotyped particles, replicase assays) in lower safety containment laboratories are sufficient for early screening. B) Identify inhibitors to virus replication of one or more of the members of the virus families discussed previously. Modeling data for broad-spectrum inhibition of replication can be used to begin intermediate development at the Phase II stage. The screening should assess in vitro antiviral activity, in vitro parameters of host response, and cytotoxicity.
Phase II:
The objective of this phase is to optimize the lead compound identified in Phase 1 through medicinal chemistry, formulation or bioengineering approaches to enhance in vitro activity against viral infections of interest . Further assessment of antiviral activity will be provided through preclinical efficacy studies. This stage will require development of working stocks of appropriate strains of virus(es) for testing if not developed in Phase I and performance within high containment laboratories.
Phase III:
PHASE III: Preclinical development of down-selected candidates to support submission of an application for an IND. Construction of a Development Plan through consultation with a sponsor and the U.S. Food and Drug Administration (FDA). Discussions and preparations would include identification of appropriate lead therapeutic(s), animal models, additional animal model studies, development of Good Manufacturing Practices (GMPs) and the conduct of safety trials.
PHASE III DUAL USE APPLICATIONS: Some of the agents listed here lack treatment options, and any therapeutic derived from this research will be of significant use for both civilian and military populations at risk.
Files
| File | Type | Posted |
|---|---|---|
| CBD244-P001.pdf | ||
| CBD_SBIR_244_R1.pdf |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity